Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response. 2017

Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
Ulyanovsk State University, 42, Leo Tolstoy Street, Russia, Ulyanovsk, 432017. Russian Federation.

BACKGROUND Polychemotherapy in ovarian cancer (OC) is the second major component of treatment. However, treatment with cytostatics is stopped in 25% of cases because of significant side effects. It is shown that concentration of certain cytokines and their balance is largely formed in accordance with a genetic polymorphism. OBJECTIVE The objective of the study was to evaluate the cytokine status of blood serum of patients with ovarian cancer with different tumor response to neoadjuvant chemotherapy (NACT). METHODS Patients received 2 courses NACT according to the scheme AP. The levels of IL-1β and IL-1Ra, IL-10, TNF-α in blood serum were determined by solid phase ELISA. For molecular genetic studies we selected polymorphic variants in the promoters of the gene represented in dbS`NP NCBI and SNP500 Cancer databases. RESULTS The sharply declined in patients with ovarian cancer compared with the normal, level of IL-1β correlates with increased levels of IL-1RA. It is found that 75% of patients who had progression of the disease after NACT bear CT genotype of gene IL-1β associated with a low expression of the cytokine, while the TT genotype, providing a high level of the expression of IL-1β gene had met only 25% among patients in this group. At the same time 70% of patients with a complete response are the carriers of the T allele, while a complete response was associated with a higher level of IL-1β than in the progression group. Low secretion of TNF-α in all types of tumor response when testing TNF-α G-308A gene polymorphisms was associated with carriage of GA and AA genotypes, which are associated with low production of this cytokine. Increased compared to the control IL-10 production in patients with ovarian cancer associated with genotype replacement at position 1082 G/A IL-10 gene, which occured in 10% of patients with a complete response and 25% of patients with tumor progression after NACT. CONCLUSIONS All the studied polymorphisms of IL-1β, IL-10 and TNF-α genes in patients with OC are associated with the level of these cytokines and tumor NACT response.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D020360 Neoadjuvant Therapy Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy. Neoadjuvant Chemoradiation,Neoadjuvant Chemoradiation Therapy,Neoadjuvant Chemoradiation Treatment,Neoadjuvant Chemoradiotherapy,Neoadjuvant Chemotherapy,Neoadjuvant Chemotherapy Treatment,Neoadjuvant Radiation,Neoadjuvant Radiation Therapy,Neoadjuvant Radiation Treatment,Neoadjuvant Radiotherapy,Neoadjuvant Systemic Therapy,Neoadjuvant Systemic Treatment,Neoadjuvant Treatment,Chemoradiation Therapy, Neoadjuvant,Chemoradiation Treatment, Neoadjuvant,Chemoradiation, Neoadjuvant,Chemoradiotherapy, Neoadjuvant,Chemotherapy Treatment, Neoadjuvant,Chemotherapy, Neoadjuvant,Neoadjuvant Chemoradiation Therapies,Neoadjuvant Chemoradiation Treatments,Neoadjuvant Chemoradiations,Neoadjuvant Chemoradiotherapies,Neoadjuvant Chemotherapies,Neoadjuvant Chemotherapy Treatments,Neoadjuvant Radiation Therapies,Neoadjuvant Radiation Treatments,Neoadjuvant Radiations,Neoadjuvant Radiotherapies,Neoadjuvant Systemic Therapies,Neoadjuvant Systemic Treatments,Neoadjuvant Therapies,Neoadjuvant Treatments,Radiation Therapy, Neoadjuvant,Radiation Treatment, Neoadjuvant,Radiation, Neoadjuvant,Radiotherapy, Neoadjuvant,Systemic Therapy, Neoadjuvant,Systemic Treatment, Neoadjuvant,Therapy, Neoadjuvant,Therapy, Neoadjuvant Chemoradiation,Therapy, Neoadjuvant Radiation,Therapy, Neoadjuvant Systemic,Treatment, Neoadjuvant,Treatment, Neoadjuvant Chemoradiation,Treatment, Neoadjuvant Chemotherapy,Treatment, Neoadjuvant Radiation,Treatment, Neoadjuvant Systemic

Related Publications

Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
December 2011, Journal of gynecologic oncology,
Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
November 2018, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
January 2021, Frontiers in oncology,
Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
December 2018, Chinese clinical oncology,
Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
August 2004, Expert review of anticancer therapy,
Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
January 2002, European journal of gynaecological oncology,
Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
June 2020, Gynecologic oncology,
Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
June 2021, Anticancer research,
Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
January 2024, Cancer research and treatment,
Inna I Antoneeva, and Tatyana V Abakumova, and Dinara R Dolgova, and Tatyana P Gening, and Sabina S Pirmamedova, and Dinara F Myasnikova, and Snezhanna O Gening
July 2021, Gynecologic oncology,
Copied contents to your clipboard!